TAK 880
Alternative Names: TAK-880Latest Information Update: 13 Nov 2023
At a glance
- Originator Takeda
- Class Immunoglobulins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Immunodeficiency disorders
Most Recent Events
- 13 Nov 2023 Preregistration for Immunodeficiency disorders in European Union (IV) (Takeda pipeline, November 2023)
- 31 Jul 2023 Takeda plans regulatory filing with EMA in EU for immunodeficiency disorders (Takeda pipeline; July 2023)
- 19 Jun 2023 Takeda plans for filing of TAK 880 for Immunodeficiency disorders in EU in 2023 (Takeda pipeline, June 2023)